On March 17, 2026 ArriVent BioPharma, Inc. (Company or ArriVent) (Nasdaq: AVBP), a clinical-stage company dedicated to accelerating the global development of innovative biopharmaceutical therapeutics, reported two poster presentations at the 2026 American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting taking place in San Diego, California April 17-22.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Preclinical findings for EGFR inhibitor firmonertinib will highlight high resolution crystal structure data supporting the ongoing pivotal Phase 3 study in frontline EGFR exon 20 insertion mutant non-small cell lung cancer (NSCLC). ArriVent in partnership with Aarvik Therapeutics, Inc. (Aarvik) will also present preclinical data on ARR-002, a novel dual-target MUC16/NaPi2b tetravalent antibody drug conjugate (ADC), characterizing its superior ADC potential in ovarian and endometrial cancers and planned advancement towards clinical evaluation. Data for ARR-002 will also be presented as part of an oral presentation by Aarvik at the Clinical Research Mini Symposium.

Abstract Highlights and Presentation Details

Discovery and Characterization of Firmonertinib, a Novel EGFR Inhibitor with Broad Activity Against both EGFR Classical and Exon 20 Insertion Mutations

Abstract Number: 2745

Time and Date: Tuesday April 21, 2026 from 2 – 5 PM PT

Session: Experimental and Molecular Therapeutics / Tyrosine Kinase, Phosphatase, & Other Inhibitors
Poster Location: Section 18, Board 9, Number 5871

Lung cancers with classical EGFR mutations respond to approved EGFR inhibitors, whereas those with EGFR exon 20 insertion (ex20ins) mutations have limited sensitivity and few treatment options. Firmonertinib is a novel, brain-penetrant irreversible EGFR inhibitor with early clinical evidence supporting activity against uncommon mutations, including ex20ins and PACC variants, and is approved in China for frontline classical and second line exon20ins EGFR mutant NSCLC. Preclinical characterization of firmonertinib demonstrated:

·

High potency inhibition of EGFR harboring classical and ex20ins mutations using a series of structural, biochemical, cell line and xenograft data

·

Strong anti-tumor activity and high brain penetrance reinforced across multiple in vitro and in vivo models

·

Findings support the structural mechanism of broad EGFR binding and inhibition by firmonertinib

AV-P138-ADC (ARR-002), a Novel MUC16/NaPi2b Dual-target Tetravalent ADC, for the Treatment of Ovarian and Endometrial Cancers

Abstract Number: 5757

Time and Date: Monday April 20, 2026 from 9 AM – 12 PM PT

Session: Clinical Research / Targeted Antigen Therapies and Immunity

Poster Location: Section 49, Board 12, Number 2660

Dual-target ADCs aim to overcome challenges underlying the high failure rate of single-target ADCs in the clinic including limited internalization, low payload delivery, and heterogeneous target expression in tumors. MUC16 and NaPi2b are highly expressed on ovarian and endometrial cancers with limited expression in normal tissues, making them ideal co-targets. ARR-002 utilizes a novel tetravalent format to fully target both MUC16 and NaPi2b. This dual targeting approach is designed to be more active and overcome tumor escape mechanisms that limit single target ADCs. Initial preclinical characterization of ARR-002 demonstrated:

·

Effective binding to individual targets, simultaneous engagement of both targets, and enhanced internalization vs. single-target antibody controls

·

Superior in vivo efficacy vs. single-target ADCs in the OVCAR-3 xenograft model

·

The potential for a wider therapeutic window based on a favorable tolerability profile in cynomolgus monkeys, consisting of reversible hematologic findings at a higher maximum tolerated single dose vs. other approaches in development

Mini Symposium Details

MUlti-epitope Targeting Tetravalent Antibody (MUTTA) Platform for Developing NextGen ADCs with an Improved Therapeutic Window

Abstract Number: 6758

Time and Date: Tuesday April 21, 2026 from 2:30 – 4:30 PM PT

Session: Clinical Research / Targeted Therapy: Data Driven Approaches and Novel Drugs

(Press release, ArriVent Biopharma, MAR 17, 2026, View Source [SID1234663607])